Francesco Testa1, Paolo Melillo1, Valentina Di Iorio1, Ada Orrico1, Marcella Attanasio1, Settimio Rossi1, Francesca Simonelli2. 1. Multidisciplinary Department of Medical, Surgical, and Dental Sciences, Eye Clinic, Second University of Naples, Naples, Italy. 2. Multidisciplinary Department of Medical, Surgical, and Dental Sciences, Eye Clinic, Second University of Naples, Naples, Italy. Electronic address: francesca.simonelli@unina2.it.
Abstract
PURPOSE: To evaluate disease progression in a cohort of patients with a clinical and genetic diagnosis of Stargardt disease. DESIGN: Longitudinal cohort study. PARTICIPANTS: A total of 56 selected patients with a clinical and molecular diagnosis of Stargardt disease, an early age of onset, and a median follow-up length of 2 years. METHODS: Patients underwent routine examination, including full-field electroretinography, microperimetry, and optical coherence tomography. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), mean retinal sensitivity, fixation stability, preferred retinal locus, inner segment/outer segment (IS/OS) junction loss, and atrophic lesion area. RESULTS: A total of 56 patients with a mean age at disease onset of 15.3 years (range, 3-28 years), a mean disease duration of 12.1 years, and a mean age at baseline of 27.4 years were analyzed. The median BCVA was 20/200 in both eyes. Optical coherence tomography parameters (IS/OS alteration and retinal pigment epithelium lesion area) were obtained in only 49 patients because the signal quality was poor in the remaining 7 patients. Optical coherence tomography revealed a mean retinal pigment epithelium lesion area of 2.6 mm(2), preserved foveal IS/OS in 4.1% of patients, loss of foveal IS/OS in 59.2% of patients, and extensive loss of macular IS/OS in 36.7% of patients. Microperimetric findings showed a reduced macular sensitivity (mean, 10 decibels [dB]) and an unstable fixation in half of the patient cohort. The longitudinal analysis showed a significant progressive reduction of BCVA and macular sensitivity (at an estimated rate of 0.04 decimals and 1.19 dB/year, respectively) associated with a significant enlargement of retinal pigment epithelium lesion area (0.282 mm(2)/year). No significant changes in ophthalmoscopic findings and electroretinographic responses were detected. CONCLUSIONS: This study highlights the importance of microperimetry and optical coherence tomography in monitoring patients with Stargardt disease. Quantifying the decline of visual functionality and detecting morphologic macular changes prove useful in evaluating disease progression over a short-term follow-up and should be taken into account for the design of future clinical trials of gene therapy to treat retinal dystrophy.
PURPOSE: To evaluate disease progression in a cohort of patients with a clinical and genetic diagnosis of Stargardt disease. DESIGN: Longitudinal cohort study. PARTICIPANTS: A total of 56 selected patients with a clinical and molecular diagnosis of Stargardt disease, an early age of onset, and a median follow-up length of 2 years. METHODS:Patients underwent routine examination, including full-field electroretinography, microperimetry, and optical coherence tomography. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), mean retinal sensitivity, fixation stability, preferred retinal locus, inner segment/outer segment (IS/OS) junction loss, and atrophic lesion area. RESULTS: A total of 56 patients with a mean age at disease onset of 15.3 years (range, 3-28 years), a mean disease duration of 12.1 years, and a mean age at baseline of 27.4 years were analyzed. The median BCVA was 20/200 in both eyes. Optical coherence tomography parameters (IS/OS alteration and retinal pigment epithelium lesion area) were obtained in only 49 patients because the signal quality was poor in the remaining 7 patients. Optical coherence tomography revealed a mean retinal pigment epithelium lesion area of 2.6 mm(2), preserved foveal IS/OS in 4.1% of patients, loss of foveal IS/OS in 59.2% of patients, and extensive loss of macular IS/OS in 36.7% of patients. Microperimetric findings showed a reduced macular sensitivity (mean, 10 decibels [dB]) and an unstable fixation in half of the patient cohort. The longitudinal analysis showed a significant progressive reduction of BCVA and macular sensitivity (at an estimated rate of 0.04 decimals and 1.19 dB/year, respectively) associated with a significant enlargement of retinal pigment epithelium lesion area (0.282 mm(2)/year). No significant changes in ophthalmoscopic findings and electroretinographic responses were detected. CONCLUSIONS: This study highlights the importance of microperimetry and optical coherence tomography in monitoring patients with Stargardt disease. Quantifying the decline of visual functionality and detecting morphologic macular changes prove useful in evaluating disease progression over a short-term follow-up and should be taken into account for the design of future clinical trials of gene therapy to treat retinal dystrophy.
Authors: Fred K Chen; Praveen J Patel; Andrew R Webster; Peter J Coffey; Adnan Tufail; Lyndon Da Cruz Journal: Retina Date: 2011-02 Impact factor: 4.256
Authors: Elliott H Sohn; Fred K Chen; Gary S Rubin; Anthony T Moore; Andrew R Webster; Robert E MacLaren Journal: Ophthalmology Date: 2010-02-19 Impact factor: 12.079
Authors: John E Legarreta; Giovanni Gregori; Robert W Knighton; Omar S Punjabi; Geeta A Lalwani; Carmen A Puliafito Journal: Am J Ophthalmol Date: 2008-03-14 Impact factor: 5.258
Authors: Christian Ahlers; Erich Götzinger; Michael Pircher; Isabelle Golbaz; Franz Prager; Christopher Schütze; Bernhard Baumann; Christoph K Hitzenberger; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2009-09-24 Impact factor: 4.799
Authors: Fred K Chen; Praveen J Patel; Wen Xing; Michael D Crossland; Catey Bunce; Gary S Rubin; Lyndon Da Cruz Journal: Optom Vis Sci Date: 2011-06 Impact factor: 1.973
Authors: Vivienne C Greenstein; Rodrigo A V Santos; Stephen H Tsang; R Theodore Smith; Gaetano R Barile; William Seiple Journal: Retina Date: 2008-10 Impact factor: 4.256
Authors: Christopher G Kiss; Wolfgang Geitzenauer; Christian Simader; Giovanni Gregori; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2009-01-10 Impact factor: 4.799
Authors: Fred K Chen; Praveen J Patel; Wen Xing; Catey Bunce; Catherine Egan; Adnan T Tufail; Peter J Coffey; Gary S Rubin; Lyndon Da Cruz Journal: Invest Ophthalmol Vis Sci Date: 2009-03-25 Impact factor: 4.799
Authors: Maria Fernanda Abalem; Benjamin Otte; Chris Andrews; Katherine A Joltikov; Kari Branham; Abigail T Fahim; Dana Schlegel; Cynthia X Qian; John R Heckenlively; Thiran Jayasundera Journal: Am J Ophthalmol Date: 2017-10-14 Impact factor: 5.258
Authors: Tommaso Verdina; Vivienne C Greenstein; Andrea Sodi; Stephen H Tsang; Tomas R Burke; Ilaria Passerini; Rando Allikmets; Gianni Virgili; Gian Maria Cavallini; Stanislao Rizzo Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-04-02 Impact factor: 3.117
Authors: Etienne M Schönbach; Rupert W Strauss; Beatriz Muñoz; Yulia Wolfson; Mohamed A Ibrahim; David G Birch; Eberhart Zrenner; Janet S Sunness; Michael S Ip; SriniVas R Sadda; Sheila K West; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2020-07-01 Impact factor: 7.389
Authors: Paolo Melillo; Francesco Testa; Settimio Rossi; Valentina Di Iorio; Ada Orrico; Alberto Auricchio; Francesca Simonelli Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799